Longaevus Technologies Ltd. has announced the spin-off of Elastin Biosciences following breakthrough preclinical results of three of its assets. Elastin Biosciences has successfully conducted experiments and identified three novel drug combinations that inhibit elastin degradation and foster its deposition, leading to an increase in elastin expression by 5-fold, and improving aortic elasticity in aged mice in vivo.